262 related articles for article (PubMed ID: 24325451)
21. Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.
Lee MH; Lee DM; Kim SS; Cheong JY; Cho SW
J Med Virol; 2011 Jul; 83(7):1178-86. PubMed ID: 21567421
[TBL] [Abstract][Full Text] [Related]
22. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
Leung N; Peng CY; Hann HW; Sollano J; Lao-Tan J; Hsu CW; Lesmana L; Yuen MF; Jeffers L; Sherman M; Min A; Mencarini K; Diva U; Cross A; Wilber R; Lopez-Talavera J
Hepatology; 2009 Jan; 49(1):72-9. PubMed ID: 19065670
[TBL] [Abstract][Full Text] [Related]
23. Prediction of response to entecavir therapy in patients with HBeAg-positive chronic hepatitis B based on on-treatment HBsAg, HBeAg and HBV DNA levels.
Shin JW; Jung SW; Park BR; Kim CJ; Eum JB; Kim BG; Jeong ID; Bang SJ; Lee SH; Kim SR; Park NH
J Viral Hepat; 2012 Oct; 19(10):724-31. PubMed ID: 22967104
[TBL] [Abstract][Full Text] [Related]
24. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.
Seto WK; Hui AJ; Wong VW; Wong GL; Liu KS; Lai CL; Yuen MF; Chan HL
Gut; 2015 Apr; 64(4):667-72. PubMed ID: 24833635
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients.
Qiu YW; Huang LH; Yang WL; Wang Z; Zhang B; Li YG; Su TT; Zhou HY; Xu W; Wang XD; Dai YP; Gan JH
Int J Infect Dis; 2016 Feb; 43():43-48. PubMed ID: 26523639
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
[TBL] [Abstract][Full Text] [Related]
27. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.
Zoulim F; Carosi G; Greenbloom S; Mazur W; Nguyen T; Jeffers L; Brunetto M; Yu S; Llamoso C
J Hepatol; 2015 Jan; 62(1):56-63. PubMed ID: 25176615
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
29. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
30. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.
Pan HY; Pan HY; Song WY; Zheng W; Tong YX; Yang DH; Dai YN; Chen MJ; Wang MS; Huang YC; Zhang JJ; Huang HJ
J Viral Hepat; 2017 Nov; 24 Suppl 1():29-35. PubMed ID: 29082652
[TBL] [Abstract][Full Text] [Related]
32. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
[TBL] [Abstract][Full Text] [Related]
33. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely.
Chevaliez S; Hézode C; Bahrami S; Grare M; Pawlotsky JM
J Hepatol; 2013 Apr; 58(4):676-83. PubMed ID: 23219442
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
35. Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis B e antigen negative chronic hepatitis B patients receiving nucleoside/nucleotide analogues.
Wong GL; Chan HL; Lo AO; Chan HY; Tse CH; Chim AM; Wong VW
Antivir Ther; 2013; 18(8):979-86. PubMed ID: 23744529
[TBL] [Abstract][Full Text] [Related]
36. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
[TBL] [Abstract][Full Text] [Related]
37. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
38. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
39. Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.
Hsu WF; Chen CF; Lai HC; Su WP; Lin CH; Chuang PH; Chen SH; Chen CH; Wang HW; Huang GT; Peng CY
Liver Int; 2018 Apr; 38(4):627-635. PubMed ID: 28857411
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B surface antigen levels after hepatitis B e-antigen seroclearance: a longitudinal follow-up study.
Fung J; Seto WK; Wong DK; Lai CL; Yuen MF
Liver Int; 2015 Mar; 35(3):854-9. PubMed ID: 24840542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]